Diagnostic application of next-generation sequencing in ZMYM2-FGFR1 8p11 myeloproliferative syndrome: A case report. Issue 8 (2nd August 2016)

• Record Type: Journal Article
• Authors: Wang, Yadan; Wu, Xiaofei; Deng, Jun; Yu, Hao; Xu, Ren; Zhu, Zhiyi; Tu, Shichun; Hu, Yu
• Is Part Of: Cancer biology & therapy. Volume 17:Issue 8(2016)
• Page Start: 785
• Page End: 789
• Publication Date: 2016-08-02
• Subjects: 8p11 myeloproliferative syndrome -- ASXL1 -- eosinophilia -- gene rearrangement -- IKZF1 -- leukocytosis -- next-generation sequencing -- whole-genome sequencing -- ZMYM2-FGFR1; 616.99406
• DOI: 10.1080/15384047.2016.1210727
• Languages: English
• ISSNs: 1538-4047

Abstract

ABSTRACT: The 8p11 myeloproliferative syndrome (EMS), also known as 8p11 myeloproliferative neoplasm (8p11 MPN), is a collection of rare hematologic malignancies that are associated with fusion genes involving the tyrosine kinase receptor gene FGFR1 in chromosome 8p11. The entity is an aggressive disease with a high rate of transformation to acute myeloid leukemia (AML) and pathologically characterized by its associated eosinophilia. In this study, we reported a distinctive EMS case featuring an in-frame ZMYM2-FGFR1 fusion gene identified by next-generation sequencing technology (NGS). This patient exhibited not only typical EMS signs including elevated white blood cells in peripheral blood and hypercellular bone marrow with marked leukocytosis, but also exceptional characteristics including erythrocytosis in blood and bone marrow basophilia. Moreover, we detected 2 novel genomic mutations in 2 known leukemogenic genes, IKZF1 and ASXL1 . Whether these 2 mutations play a part in EMS pathogenesis or contribute to its specific presentations clinically remain to be determined. In summary, we present a unique EMS case involving a ZMYM2-FGFR1 fusion with distinctive hematologic characteristics.